- Home
- ADAP
as 04-18-2025 1:30pm EST
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.
| Founded: | 2008 | Country: | United Kingdom |
| Employees: | N/A | City: | ABINGDON, OXFORDSHIRE |
| Market Cap: | 71.6M | IPO Year: | 2015 |
| Target Price: | $1.83 | AVG Volume (30 days): | 2.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.30 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.20 - $1.48 | Next Earning Date: | 05-14-2025 |
| Revenue: | $178,032,000 | Revenue Growth: | 195.34% |
| Revenue Growth (this year): | -76.16% | Revenue Growth (next year): | 65.49% |
Latest Adaptimmune Therapeutics plc News
ADAP Breaking Stock News: Dive into ADAP Ticker-Specific Updates for Smart Investing
Zacks Small Cap Research
25 days ago
ADAP 4Q24 Earnings Review: EPS Miss on 1x Restructuring/Impairment Costs; Potential Capital Raise Adds Risk to the Story
GuruFocus.com
a month ago
Earnings To Watch: Adaptimmune Therapeutics PLC (ADAP) Reports Q4 2024 Result
GuruFocus.com
a month ago
Adaptimmune Therapeutics PLC (ADAP) (Q4 2024) Earnings Call Highlights: Strategic Growth and ...
Zacks Small Cap Research
a month ago
ADAP: 4Q24 Business Update: Tecelra Launch Progressing + Incremental Cost Savings; Banker-Led Process to Explore Strategic Options
Newsfile
a month ago
Adaptimmune Provides Q4 and Full Year 2024 Business Update
FastCompany
a month ago
From cancer vaccines to COPD treatments, these 10 companies are developing innovative medicines
Newsfile
a month ago
Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025
Simply Wall St.
2 months ago
Adaptimmune Therapeutics plc's (NASDAQ:ADAP) top owners are retail investors with 50% stake, while 25% is held by hedge funds
Compare ADAP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ADAP Adaptimmune Therapeutics plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.